Press release - 13/04/2021 Evotec’s BRIDGE “beLAB2122” leverages academic innovation from our region Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.https://www.gesundheitsindustrie-bw.de/en/article/press-release/evotecs-bridge-belab2122-leverages-academic-innovation-our-region
Quantum Technology Ulm - 08/04/2021 Diamonds for life sciences innovations The world's first commercial quantum computer,’IBM Q System One’, is now in operation in Ehningen near Stuttgart. This is a major leap forward in quantum technology in Germany. It marks the point at which conventional computers reach their limits. The University of Ulm is involved in three of six collaborative projects being funded by the Baden-Württemberg Ministry of Economic Affairs, Labour and Housing Construction.https://www.gesundheitsindustrie-bw.de/en/article/news/diamonds-life-sciences-innovations
Press release - 30/03/2021 Celonic and CureVac announce agreement to manufacture over 100 million doses of CureVac's Covid-19 vaccine candidate, CVnCoV CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on mRNA and Celonic Group, a premium biopharmaceutical Contract Development and Manufacturing Organization specializing in the development and production of Advanced Therapy Medicinal Products and mammalian cell line-expressed bio-therapeutics, announced their partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.https://www.gesundheitsindustrie-bw.de/en/article/press-release/celonic-and-curevac-announce-agreement-manufacture-over-100-million-doses-curevacs-covid-19-vaccine-candidate-cvncov
Press release - 24/03/2021 Vaccination against mutated protein tested in brain tumor patients for the first time Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccination-against-mutated-protein-tested-brain-tumor-patients-first-time
Press release - 24/03/2021 Liver cancer: which patients benefit from immunotherapy? Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…https://www.gesundheitsindustrie-bw.de/en/article/press-release/liver-cancer-which-patients-benefit-immunotherapy
Microfluidics in medical technology - 24/03/2021 Ultra-compact: valves with shape memory actuators Karlsruhe-based company memetis shows that this is possible. Intelligent components for controlling fluids open up huge potential in the medical technology and biotechnology sectors - from vaccine development and cell line analysis to drug research and point-of-care solutions.https://www.gesundheitsindustrie-bw.de/en/article/news/ultra-compact-valves-shape-memory-actuators
Press release - 23/03/2021 CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 and a strain of the original SARS-CoV-2 B1 lineage (BavPat1) in a transgenic mouse model.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrates-protection-against-sars-cov-2-b1351-variant-south-african-variant-precli